Risankizumab

Recently published in the British Journal of Dermatology, AbbVie’s phase 4 head-to-head study shows risankizumab demonstrates superiority over apremilast for the treatment of adults with moderate plaque psoriasis.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

In this Healio exclusive video, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses his American Academy of Dermatology Annual Meeting presentation on biologics and biosimilars in psoriasis treatment.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses a study following the use of oral roflumilast to treat plaque psoriasis.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on a study of orismilast, a novel phosphodiesterase-4 inhibitor, in the treatment of psoriasis.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses DICE Therapeutics’ phase 1 study of DC-806, a new oral interleukin-17A inhibitor, as an alternative to injectable medications in psoriasis treatment.

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses the benefits of switching patients with psoriasis to risankizumab after suboptimal response from secukinumab or ixekizumab treatment.

Topline findings from the phase 3 INSPIRE induction trial showed that Skyrizi, met the primary endpoint of achieving clinical remission at 12 weeks in adults with moderately to severely active ulcerative colitis, AbbVie announced.

NEW ORLEANS — Patients with psoriasis who had suboptimal results with prior interleukin-17 therapy experienced beneficial results with risankizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.

In a Healio video exclusive, Remo Panaccione, MD, noted the cumulative benefit of Skyrizi and Rinvoq for the induction and maintenance treatment of patients with inflammatory bowel disease.